Researchers have created a promising new combination immunotherapy that could improve treatment for ovarian cancer, a disease that often resists standard immunotherapies. The study combines two immune-based treatments to produce a stronger and longer-lasting anti-tumor response.
The first component uses engineered T cells that specifically target the folate receptor alpha, a protein found in abundance on ovarian cancer cells. These modified T cells also release bispecific T cell engagers (BiTEs), which help recruit and activate the patient’s own immune cells to destroy cancer cells. The second component is an immune checkpoint inhibitor that helps sustain the immune system’s attack by preventing immune exhaustion.
In preclinical models and patient-derived tumor samples, the combination reshaped the tumor microenvironment, enhancing immune activity and providing durable tumor control. When a therapeutic cancer vaccine was added after treatment, the anti-tumor response became e